Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEORAF: Neoadjuvant Encorafenib, Cetuximab N01 and mFOLFOX6 in BRAF V600E Mutated Colorectal Cancer
NCT07789210Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, KL-140 in colorectal cancer (CRC), sponsored by Zhejiang University. Started Jun 2026; status: recruiting.
02
Drugs
encorafenibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07789210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789210.